Acute myelogenous leukemia in adolescents and young adults.

about

Acute myelogenous leukemia in adolescents and young adults.

Item

http://www.wikidata.org/entity/Q52318200

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Acute myelogenous leukemia in adolescents and young adults.

@en

Acute myelogenous leukemia in adolescents and young adults.

@nl

type

Item

label

Acute myelogenous leukemia in adolescents and young adults.

@en

Acute myelogenous leukemia in adolescents and young adults.

@nl

prefLabel

Acute myelogenous leukemia in adolescents and young adults.

@en

Acute myelogenous leukemia in adolescents and young adults.

@nl

P1476

Acute myelogenous leukemia in adolescents and young adults

@en

P2093

Raul C Ribeiro

http://www.w3.org/2001/XMLSchema#string

Richard F Schlenk

http://www.w3.org/2001/XMLSchema#string

P2860

The incidence of secondary leukemias

Reduced retinoic acid-sensitivities of nuclear receptor corepressor binding to PML- and PLZF-RARalpha underlie molecular pathogenesis and treatment of acute promyelocytic leukemia

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

The origin and evolution of mutations in acute myeloid leukemia

Survival of European adolescents and young adults diagnosed with cancer in 2000-07: population-based data from EUROCARE-5.

Racial and ethnic disparities in the survival of adolescents and young adults with acute myeloid leukemia: a retrospective study using the US National Cancer Data Base.

Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry.

Retinoic acid and arsenic trioxide for acute promyelocytic leukemia.

Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531.

P304

e27089

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/PBC.27089

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Matthew A Kutny

Ursula Creutzig

Ronald Barr

P577

2018-04-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29667722

http://www.w3.org/2001/XMLSchema#string

P932

6105504

http://www.w3.org/2001/XMLSchema#string